ERBB2 and neoplasm: Women with high CBR1 tumour expressions were slightly more likely to have positive lymph nodes, stage III and IV disease, HER2 positive status and to have received adjuvant chemotherapy, hormone therapy and trastuzumab therapy (Table 1).